Literature DB >> 30645774

Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Alison L Van Dyke1, Meredith S Shiels1, Gieira S Jones1, Ruth M Pfeiffer2, Jessica L Petrick3, Jennifer L Beebe-Dimmer4,5, Jill Koshiol1.   

Abstract

BACKGROUND: Biliary tract cancers (BTCs) are rare but deadly cancers (gallbladder cancer [GBC], intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], and ampulla of Vater cancer [AVC]). A recent US study reported increasing GBC incidence among people younger than 45 years and blacks; however, it did not examine trends for other biliary tract sites.
METHODS: This study characterized demographic differences in BTC incidence rates and time trends by anatomic site. Population-based North American Association of Central Cancer Registries data were used to calculate age-adjusted incidence rates, incidence rate ratios (IRRs), and estimated annual percent changes (eAPCs) for 1999-2013 by site and demographic group. For sites with significant differences in eAPC by age group, IRRs were compared by age group.
RESULTS: GBC incidence rates declined among women (eAPC, -0.5%/y; P = .01) and all racial/ethnic groups except for non-Hispanic blacks, among whom rates increased (1.8%/y; P < .0001). Although GBC rates increased among 18- to 44-year-olds (eAPC, 1.8%/y; P = .01), they decreased among people 45 years old or older (-0.4%/y; P = .009). Sex (P < .0001) and racial/ethnic differences (P = .003 to .02) in GBC incidence were larger for younger people than older people. During this period, ICC (eAPC, 3.2%/y; P < .0001) and ECC rates (1.8%/y; P = .001) steadily increased across sex and racial/ethnic groups. Although AVC incidence rates increased among younger adults (eAPC, 1.8%/y; P = .03) but not older adults (-0.20%/y; P = .30), sex and racial/ethnic IRRs did not differ by age.
CONCLUSIONS: Differential patterns of BTC rates and temporal trends have been identified by anatomic site and demographic groups. These findings highlight the need for large pooling projects to evaluate BTC risk factors by anatomic site.
© 2019 American Cancer Society.

Entities:  

Keywords:  United States; biliary tract; cancer; incidence; trends

Mesh:

Year:  2019        PMID: 30645774      PMCID: PMC6467796          DOI: 10.1002/cncr.31942

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  Changing patterns of gallbladder carcinoma in New Mexico.

Authors:  Jehad Barakat; Jeffrey C Dunkelberg; Thomas Y Ma
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

4.  Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States.

Authors:  Anna L Beavis; Patti E Gravitt; Anne F Rositch
Journal:  Cancer       Date:  2017-01-23       Impact factor: 6.860

5.  Gallstones, cholecystectomy, and risk of digestive system cancers.

Authors:  Leticia Nogueira; Neal D Freedman; Eric A Engels; Joan L Warren; Felipe Castro; Jill Koshiol
Journal:  Am J Epidemiol       Date:  2014-01-26       Impact factor: 4.897

6.  Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years.

Authors:  Yuhree Kim; Aslam Ejaz; Amit Tayal; Gaya Spolverato; John F P Bridges; Robert A Anders; Timothy M Pawlik
Journal:  Cancer       Date:  2014-06-10       Impact factor: 6.860

7.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

8.  Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973-2007.

Authors:  Steven R Alberts; Janet J Kelly; Ramkumar Ashokkumar; Anne P Lanier
Journal:  Int J Circumpolar Health       Date:  2012-03-20       Impact factor: 1.228

9.  Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study.

Authors:  Rubayat Rahman; Eduardo J Simoes; Chester Schmaltz; Christian S Jackson; Jamal A Ibdah
Journal:  Cancer Med       Date:  2017-03-20       Impact factor: 4.452

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare.

Authors:  Jessica L Petrick; Baiyu Yang; Sean F Altekruse; Alison L Van Dyke; Jill Koshiol; Barry I Graubard; Katherine A McGlynn
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

View more
  31 in total

1.  Challenges in elucidating cholangiocarcinoma etiology.

Authors:  Sarah S Jackson; Andrea A Florio; Katherine A McGlynn; Jessica L Petrick
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

2.  The Chile Biliary Longitudinal Study: A Gallstone Cohort.

Authors:  Jill Koshiol; Vanessa Van De Wyngard; Emma E McGee; Paz Cook; Ruth M Pfeiffer; Noldy Mardones; Karie Medina; Vanessa Olivo; Karen Pettit; Sarah S Jackson; Fabio Paredes; Raúl Sanchez; Andrea Huidobro; Miguel Villaseca; Enrique Bellolio; Hector Losada; Juan Carlos Roa; Allan Hildesheim; Juan Carlos Araya; Catterina Ferreccio
Journal:  Am J Epidemiol       Date:  2021-02-01       Impact factor: 4.897

3.  The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation.

Authors:  Safak Gül-Klein; Paulina Schmitz; Wenzel Schöning; Robert Öllinger; Georg Lurje; Sven Jonas; Deniz Uluk; Uwe Pelzer; Frank Tacke; Moritz Schmelzle; Johann Pratschke; Ramin Raul Ossami Saidy; Dennis Eurich
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

4.  FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.

Authors:  Sandra J Casak; Shan Pradhan; Lola A Fashoyin-Aje; Yi Ren; Yuan-Li Shen; Yuan Xu; Edwin Chiu Yuen Chow; Ye Xiong; Jeanne Fourie Zirklelbach; Jiang Liu; Rosane Charlab; William F Pierce; Nataliya Fesenko; Julia A Beaver; Richard Pazdur; Paul G Kluetz; Steven J Lemery
Journal:  Clin Cancer Res       Date:  2022-07-01       Impact factor: 13.801

5.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

6.  Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.

Authors:  Chirag Nepal; Bin Zhu; Colm J O'Rourke; Deepak Kumar Bhatt; Donghyuk Lee; Lei Song; Difei Wang; Alison L Van Dyke; Hyoyoung Choo-Wosoba; Zhiwei Liu; Allan Hildesheim; Alisa M Goldstein; Michael Dean; Juan LaFuente-Barquero; Scott Lawrence; Karun Mutreja; Mary E Olanich; Justo Lorenzo Bermejo; Catterina Ferreccio; Juan Carlos Roa; Asif Rashid; Ann W Hsing; Yu-Tang Gao; Stephen J Chanock; Juan Carlos Araya; Jesper B Andersen; Jill Koshiol
Journal:  J Hepatol       Date:  2020-12-01       Impact factor: 25.083

7.  Gallbladder and extrahepatic bile duct cancers in the Americas: Incidence and mortality patterns and trends.

Authors:  Adalberto Miranda-Filho; Marion Piñeros; Catterina Ferreccio; Volkan Adsay; Isabelle Soerjomataram; Freddie Bray; Jill Koshiol
Journal:  Int J Cancer       Date:  2020-01-21       Impact factor: 7.316

8.  Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women.

Authors:  Jessica L Petrick; Andrea A Florio; Xuehong Zhang; Anne Zeleniuch-Jacquotte; Jean Wactawski-Wende; Stephen K Van Den Eeden; Frank Z Stanczyk; Tracey G Simon; Rashmi Sinha; Howard D Sesso; Catherine Schairer; Lynn Rosenberg; Thomas E Rohan; Mark P Purdue; Julie R Palmer; Martha S Linet; Linda M Liao; I-Min Lee; Jill Koshiol; Cari M Kitahara; Victoria A Kirsh; Jonathan N Hofmann; Chantal Guillemette; Barry I Graubard; Edward Giovannucci; J Michael Gaziano; Susan M Gapster; Neal D Freedman; Lawrence S Engel; Dawn Q Chong; Yu Chen; Andrew T Chan; Patrick Caron; Julie E Buring; Gary Bradwin; Laura E Beane Freeman; Peter T Campbell; Katherine A McGlynn
Journal:  Hepatology       Date:  2020-08       Impact factor: 17.298

9.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.

Authors:  Mansi Arora; James M Bogenberger; Amro Abdelrahman; Jennifer L Leiting; Xianfeng Chen; Jan B Egan; Aradhana Kasimsetty; Elzbieta Lenkiewicz; Smriti Malasi; Pedro Luiz Serrano Uson; Bolni Marius Nagalo; Yumei Zhou; Marcela A Salomao; Heidi E Kosiorek; Esteban Braggio; Michael T Barrett; Mark J Truty; Mitesh J Borad
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-21       Impact factor: 3.288

10.  Incidence and Mortality of Cancers of the Biliary Tract, Gallbladder, and Liver by Sex, Age, Race/Ethnicity, and Stage at Diagnosis: United States, 2013 to 2017.

Authors:  Taylor D Ellington; Behnoosh Momin; Reda J Wilson; S Jane Henley; Manxia Wu; A Blythe Ryerson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-07-08       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.